You are here:
Direct Healthcare Professional Communication (DHPC) on Eylea® 40 mg/ml (aflibercept solution for intravitreal injection): higher risk of intraocular pressure increase with the pre-filled syringe
2021.04.15
Active substance: aflibercept
Bayer, in agreement with the European Medicines Agency (EMA) and the Federal Institute for Drugs and Medical Devices (BfArM), would like to inform of cases of increased intraocular pressure, which have been reported more frequently when using the Eylea pre-filled syringe, compared with administration with Luer-lock syringe of Eylea solution for injection in a vial. Incorrect handling in the preparation and injection is suspected as the most probable root cause of the observed cases of increased intraocular pressure with the Eylea pre-filled syringe.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN